AI Summary
High Tide reported Q2 2026 revenue of $179.3M with a 27% gross margin and $13.9M in Adjusted EBITDA, marking multi-quarter strength. Remexian in Germany delivered $31.6M in revenue with 27% margins and expanding market share, while the company secured a $40M senior credit facility from Bank of Montreal. Domestic store expansion and loyalty program growth underpin upside, with potential U.S. and European policy tailwinds adding optionality.
Sentiment Rationale
The quarter beat across revenue and EBITDA, margin expansion, and Remexian top-line growth validate the company’s diversified growth model. Non-dilutive financing reduces equity risk while insider buying reinforces confidence. European expansion (Germany) and potential U.S. policy shifts present catalysts for multiple quarters, though macro cannabis regulatory risk remains a consideration.
Trading Thesis
Bullish for HITI in the next 1–3 quarters on revenue/margin strength, Remexian expansion, and non-dilutive financing.
Market-Moving
- Record Q2 revenue and margin expansion beat expectations.
- Remexian Germany gaining share with 14% three-month mix.
- Bank of Montreal $40M senior secured facility reduces dilution risk.
- Canna Cabana store network grows toward 228; Ontario openings ongoing.
- U.S. regulatory shifts could affect listing policies and opportunities.
Key Facts
- Q2 2026 revenue: $179.3M, up 30% YoY.
- Gross margin 27%; Adjusted EBITDA $13.9M, eight-quarter high.
- Remexian Germany revenue $31.6M; margin 27%; tonnage 7.6.
- Bank of Montreal extends $40M senior secured facilities.
- Cabana Club 2.65M members; ELITE 178k; 221 stores in Canada.
Companies Mentioned
- High Tide Inc. (HITI): Reported quarter with record revenue and improved margins; diversified growth.
- Remexian Pharma GmbH (Remexian): German medical cannabis distributor; growing share, higher margins.
- Bank of Montreal (BMO): Provided $40M senior secured facilities to High Tide; non-dilutive funding.
- Canna Cabana (HITI.CA): Leading Canadian cannabis retailer; stores and loyalty programs drive growth.
- NuLeaf Naturals (N/A): U.S. hemp-derived CBD subsidiary pursuing CMS pilot; potential U.S. exposure.
Earnings
Category: Earnings. The release centers on quarterly results, Remexian contribution, and growth/margin trajectory alongside liquidity enhancements, consistent with a multi-geography expansion thesis.